Characterization of macrophage activation states in patients with cystic fibrosis

Background Chronic airway inflammation characterizes patients with cystic fibrosis (CF). The role of alternative macrophage activation in this disease course is unknown. Objective We evaluated markers of alternative and classical macrophage activation in the lungs of patients with CF and evaluated these characteristics in the context of Pseudomonas aeruginosa ( PA ) infection, immunomodulatory drug therapy and pulmonary function. Methods Bronchoalveolar lavage or spontaneously expectorated sputum samples were collected from 48 CF patients. Clinical data were related to macrophage surface expression of mannose receptor (MR) (up-regulated in alternatively activated macrophages) and TLR4 (up-regulated in classically activated macrophages). Also, the activity of the alternatively activated macrophage effector molecule arginase was compared among patient groups, and pro- and anti-inflammatory cytokines produced by alternatively and classically activated macrophages were measured. Results There were significant differences between PA -infected and -uninfected patients in several clinical measurements. PA -infected patients exhibited increased use of azithromycin, up-regulation of MR on CD11b+ cells and increased arginase activity in their lung samples, and had a strong inverse relationship between MR and arginase activity to FEV 1 . Upon further analysis, PA -infected patients who were treated with azithromycin had the highest arginase activity and the highest number of macrophages that were MR+TLR4−, and both of these markers were inversely related to the FEV 1 . Conclusions Our findings suggest an increase in both MR and arginase expression as pulmonary function declines in PA -infected patients with CF. These markers of an alternatively activated macrophage phenotype give cause for future study to define the function of macrophage activation states in the CF lung.